• Their concept was further expanded at the 2016 WEF in Davos, where it was discussed as a solution to the problems encountered in developing and distributing a vaccine for the Western African Ebola virus epidemic. (wikipedia.org)
  • The initial targets were the six EID viruses with known potential to cause major epidemics, being: MERS, Lassa fever, Nipah virus, Ebola, Marburg fever and Zika. (wikipedia.org)
  • At launch, Norwegian physician John-Arne Røttingen, who led the steering committee for Ebola vaccine trials, served as interim CEO, and CEPI was based at the Norwegian Institute of Public Health in Oslo. (wikipedia.org)
  • We demonstrate that NiV-G is largely devoid of the oligomannose-type glycans that in viruses such as human immunodeficiency virus type 1 and Ebola virus influence viral tropism and the host immune response. (ox.ac.uk)
  • Controls receiving rVSV-Ebola vaccine rapidly succumbed to NiV challenge, eliminating the innate immunity stimulated by the rVSV vector as a contributor to survival in monkeys challenged as early as 7 days after vaccination. (bvsalud.org)
  • These outbreaks are most often caused by Ebola virus, but at least three related viruses can also cause the disease. (cdc.gov)
  • This report describes generation of a recombinant Sudan virus and demonstrates its utility by quantifying antibody cross-reactivity between Ebola and Sudan virus glycoproteins after human infection or vaccination with a licensed Ebola virus vaccine. (cdc.gov)
  • Uganda experienced five Ebola disease outbreaks caused by Bundibugyo virus (n = 1) and Sudan virus (SUDV) (n = 4) from 2000 to 2021. (cdc.gov)
  • in the past decade the zaire strain of ebola virus (zebov) has emerged repeatedly into human populations in central africa and caused massive die-offs of gorillas and chimpanzees. (liverpool.ac.uk)
  • human recombinant antibodies to ebola virus: preparation and characteristics]. (liverpool.ac.uk)
  • human recombinant antibodies against a purified ebola virus (ev) lysate were selected from a combinatorial library of scfv-antibodies using the phage display technique. (liverpool.ac.uk)
  • protective cytotoxic t-cell responses induced by venezuelan equine encephalitis virus replicons expressing ebola virus proteins. (liverpool.ac.uk)
  • infection with ebola virus causes a severe disease accompanied by high mortality rates, and there are no licensed vaccines or therapies available for human use. (liverpool.ac.uk)
  • filovirus vaccine research efforts still need to determine the roles of humoral and cell-mediated immune responses in protection from ebola virus infection. (liverpool.ac.uk)
  • the status of current laboratory diagnostics for ebola and marburg virus infections is discussed in terms of the assays available and their interpretation. (liverpool.ac.uk)
  • ebola virus circulation in africa: a balance between clinical expression and epidemiological silence. (liverpool.ac.uk)
  • nearly thirty years after the first epidemics, ebola virus (ebov) remains hardly described, its transmission unclear and its reservoir elusive. (liverpool.ac.uk)
  • soon after the ebola fever outbreak and virus discovery in 1976 and in order to investigate the distribution of ebov in central africa, several countries including a range of ecological zones were investigated in the early 1980s, using extensive survey: central african republic (car), cameroon, chad, congo, gabon and equatorial guinea. (liverpool.ac.uk)
  • ZMapp), anti-sense phosphorodiamidate morpholino oligomers (PMO AVI-6002), lipid nanoparticle small interfering RNA (LNP-siRNA: TKM-Ebola), and an EBOV glycoprotein-based vaccine using live-attenuated recombinant vesicular stomatitis virus (rVSV-EBOGP) or a chimpanzee adenovirus (rChAd-EBOGP)-based vector. (biomedcentral.com)
  • Nonsegmented negative-strand (NNS) RNA viruses include some of the most significant human pathogens extant (rabies, ebola, respiratory syncytial, measles, mumps, Nipah viruses). (whelan-lab.org)
  • More recently, provocative studies have found high antibody seroprevalence to viruses such as Ebola, Marburg, and Lyssa viruses in multiple African countries, indicating the presence of a high number of undiagnosed cases every year, including high neutralizing titers of antibodies to rabies virus in 11% of a small cohort of asymptomatic Peruvians living in the Amazon with prior exposure to bats. (medscape.com)
  • Pteropid bats are the natural reservoir of HeV and other important zoonotic viruses such as Nipah and Ebola viruses. (cabi.org)
  • In 2018, CEPI provided up to $19 million to Oxford to develop vaccines against Lassa, Nipah, and MERS. (hexdigital.com)
  • CEPI announced a partnering agreement , worth up to US$56 million, with Inovio in April 2018, to advance DNA vaccine candidates against MERS and another of its priority diseases, Lassa fever, through to Phase 2. (pipelinereview.com)
  • We are delighted to continue our long-lasting collaboration with Themis and CEPI that has already delivered high potential vaccine candidates for Chikungunya, nearing phase 3, and Lassa fever in phase 1, both emerging infectious diseases representing a threat to global health. (pasteur.fr)
  • Lassa virus infections can respond to antiviral treatment in some cases, but there is no vaccine available. (helixbiogeninstitute.org)
  • Helix Biogen Institute is working on a Lassa virus vaccine containing both nucleoprotein and surface glycoprotein component of the Lassa virus for endemic region. (helixbiogeninstitute.org)
  • The Institute is ideally placed to develop this new conjugate sub-unit vaccine to help prevent and ultimately eliminate Lassa virus in African countries where they are most needed. (helixbiogeninstitute.org)
  • Antibodies with broad neutralizing activity are induced by adjuvant-formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein. (helixbiogeninstitute.org)
  • Helix Biogen Institute is working on the development of a Lassa virus vaccine (candidate 2) which contain the surface glycoprotein component of the Lassa virus. (helixbiogeninstitute.org)
  • Lassa virus (LV), for example, is a common cause of disease in Africa, and survivors frequently suffer from significant neurological damage. (helixbiogeninstitute.org)
  • A single inoculation of a plasmid encoding full-length Lassa nucleoprotein (LNP) can induce CD8 (+) T cell responses in mice and protect them against infection with two arenaviruses, LCMV and Pichinde virus (PV). (helixbiogeninstitute.org)
  • Lassa virus vaccine (candidate 3) that contains only nucleotide proteins is under development at Helix Biogen Institute. (helixbiogeninstitute.org)
  • Vaccination is a key element to PRRS control and while both inactivated and live attenuated PRRS vaccines are widely used neither provides sufficiently effective protection against the diversity of circulating PRRSV strains. (pirbright.ac.uk)
  • We are also exploring the potential for live attenuated PRRSV and pseudorabies virus to act as vaccine vectors for Nipah and thus provide a bivalent vaccine. (pirbright.ac.uk)
  • Knowing this, vaccinologists and veterinarians have explored the use of self spreading vaccines in animals using live attenuated viruses. (substack.com)
  • We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiV B challenge in African green monkeys. (cdc.gov)
  • Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. (ox.ac.uk)
  • Helix Biogen Institute (Known as Helix Biogen Consult) in partnership with Thelvax has initiated the development of COVID-19 candidate vaccine containing antigenic component of surface glycoprotein of SARS-CoV-2 which was expressed in E. coli. (helixbiogeninstitute.org)
  • Helix biogen Institute in collaboration with Thelvax commence the development of COVID-19 candidate 2 vaccine which also contain antigenic component of surface glycoprotein of SARS-CoV-2 expressed in insect. (helixbiogeninstitute.org)
  • By manipulating the genome of vesicular stomatitis virus we generate recombinant autonomously propogating viruses in which the single VSV attachment and fusion glycoprotein (G) has been replaced by the entry machinery of representatives from every family of enveloped viruses. (whelan-lab.org)
  • The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. (creative-biolabs.com)
  • Respiratory epithelium appears to be the major site of virus binding and subsequent infection. (medscape.com)
  • Apart from supportive care, neither a licensed vaccine nor a specific therapy is available for the treatment of the human EBOV infection [ 2 ]. (biomedcentral.com)
  • In this study, we found that EKL1C also exhibited broad-spectrum fusion inhibitory activity against human immunodeficiency virus type 1 (HIV-1) infection by interacting with the N-terminal heptad repeat 1 (HR1) of viral gp41 to block six-helix bundle (6-HB) formation. (bvsalud.org)
  • These results suggest that HR1 is a common target for the development of broad-spectrum viral fusion inhibitors and EKL1C has potential clinical application as a candidate therapeutic or preventive agent against infection by coronavirus, HIV-1, and possibly other class I enveloped viruses. (bvsalud.org)
  • Type â enveloped viruses bind to cell receptors through surface glycoproteins to initiate infection or undergo receptor-mediated endocytosis and initiate membrane fusion in the acidic environment of endocytic compartments, releasing genetic material into the cell. (bvsalud.org)
  • A DNA minigene vaccine encoding a 9-amino-acid sequence from LNP also induces CD8 (+) T cells and protects against arenavirus infection, confirming the findings. (helixbiogeninstitute.org)
  • Infection by one of the four dengue virus serotypes has been shown to confer lasting protection against homotypic re-infection, but only transient protection against a secondary heterotypic infection. (medicofem.com)
  • 2001. Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. (nationalacademies.org)
  • In addition to acute viral encephalitis, other less established and more unusual manifestations of viral infections include progressive neurologic disorders, such as postinfectious encephalomyelitis (such as may occur after measles or Nipah virus encephalitis) and conditions such as postpoliomyelitis syndrome, which has been considered by some to be as a persistent manifestation of poliovirus infection. (medscape.com)
  • An unusual CNS involvement leading to microcephaly due to infection of pregnant women by Zika virus has also been recently reported and highlights the constant need to look for new types of neurological manifestations of viral infections in humans. (medscape.com)
  • The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. (unt.edu)
  • Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different strains. (unt.edu)
  • x-linked immunodeficiency with magnesium defect, epstein-barr virus infection, and neoplasia: report of a family and literature review]. (liverpool.ac.uk)
  • objective: to investigate the clinical features and genetic characteristics of cases with x-linked immunodeficiency with magnesium defect, epstein-barr virus (ebv) infection, and neoplasia (xmen). (liverpool.ac.uk)
  • what is the impact of epstein-barr virus in peri-implant infection? (liverpool.ac.uk)
  • transcriptional profile and epstein-barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. (liverpool.ac.uk)
  • it is debated whether multiple sclerosis (ms) might result from an immunopathological response toward an active epstein-barr virus (ebv) infection brought into the central nervous system (cns) by immigrating b cells. (liverpool.ac.uk)
  • epstein-barr virus infection and type i interferon signature in patients with systemic lupus erythematosus. (liverpool.ac.uk)
  • epstein-barr (eb) virus infection has long been speculated to evoke systemic lupus erythematosus (sle). (liverpool.ac.uk)
  • since a virus infection can induce interferon (ifn) system activation, we aimed to discover the relationship between the two in the progression of sle in a chinese inpatient cohort. (liverpool.ac.uk)
  • On 20 September 2022, Uganda declared a fifth Sudan virus disease outbreak in the Mubende district, resulting in 142 confirmed and 22 probable cases by the end of the outbreak declaration on 11 January 2023. (cdc.gov)
  • We have a longstanding interest in understanding immunological mechanisms underlying protective immunity and the application of this knowledge to the development of new or improved vaccines. (pirbright.ac.uk)
  • Variant-proof and pan-coronavirus vaccines, if we can develop them, will be critical tools protecting us from variants that don't even exist yet and ideally creating more durable immunity than current vaccines. (vbivaccines.com)
  • These antibodies will then be used to identify highly conserved vaccine targets that may be engineered to induce cross-protection. (pirbright.ac.uk)
  • SARS-CoV-2 antigen-specific humoral and cellular immune responses, including neutralizing antibodies to ancestral virus and variants of concern (VOC), were measured up to six months post vaccination and compared to immune responses in historical cohorts of naïve healthy volunteers (HV) vaccinated with COH04S1 and naïve healthcare workers (HCW) vaccinated with the FDA-approved mRNA vaccine Comirnaty® (Pfizer, New York, NY, USA). (bvsalud.org)
  • After one or two COH04S1 vaccine doses, HCT/CAR-T recipients showed a significant increase in S- and N-specific binding antibody titers and neutralizing antibodies with potent activity against SARS-CoV-2 ancestral virus and VOC, including the highly immune evasive Omicron XBB.1.5 variant. (bvsalud.org)
  • In addition to serving as vaccine candidates, these recombinant viruses allow for rapid mapping of escape mutations to envelope protein directed inhibitors including monoclonal antibodies and small molecules. (whelan-lab.org)
  • The FT reported CEPI would "build the scientific and technological infrastructure for developing vaccines quickly against pathogens that emerge from nowhere to cause a global health crisis, such as Sars in 2002/03 and Zika in 2015/16", and fund research papers on the costs and process of vaccine development. (wikipedia.org)
  • Viral vector-based vaccines offer the potential to provide protection against virulent pathogens entering via the mucosal route. (pirbright.ac.uk)
  • In this study, we developed reverse genetics systems, including minigenomes and recombinant viruses, that will facilitate the study of these pathogens. (cdc.gov)
  • This vaccine platform has been used to produce vaccine candidates against multiple pathogens, including Influenza, Chikungunya, and Zika. (hexdigital.com)
  • CEPI entered a partnering agreement in January 2019, with University of Queensland, for up to US$ 10.6 million to develop a "molecular clamp" vaccine platform, a transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens. (pipelinereview.com)
  • As part of their partnering agreement with CEPI, the University of Queensland will use their molecular-clamp vaccine platform to produce vaccines against known pathogens, including Middle East Respiratory Syndrome coronavirus (MERS-CoV) and will evaluate the safety and immune response of the Influenza and MERS-CoV candidates in a phase 1 clinical trial in humans. (pipelinereview.com)
  • The goal of such studies is to ultimately inform the development of inhibitors against this group of important pathogens, and to advance the use of VSV as a vaccine vector, an oncolytic agent, and a neuronal tracer. (whelan-lab.org)
  • We replicate very slowly, and the various pathogens that want to live in and on us, the bacteria, the viruses, the protozoa, replicate very quickly. (lindau-nobel.org)
  • Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? (mdpi.com)
  • We have therefore identified and characterised conserved T cell antigens from PRRSV and are evaluating their vaccine potential using a novel vaccine vector platform based on an attenuated herpesvirus. (pirbright.ac.uk)
  • Introduction: Immune correlates of protection afforded by PHV02, a recombinant vesicular stomatitis (rVSV) vector vaccine against Nipah virus (NiV) disease, were investigated in the African green monkey (AGM) model. (bvsalud.org)
  • ChAdOx1 is a replication-deficient simian adenoviral vaccine vector. (hexdigital.com)
  • CEPI to provide initial US$4.9 million for consortium to develop a Covid-19 vaccine candidate based on measles-vector technology. (pasteur.fr)
  • As part of the Covid-19 Task Force set up in January 2020, after our isolation of the coronavirus strains detected in France, the proprietary measles vector (MV) technology was chosen to develop a vaccine against SARS-CoV-2 leveraging our extensive experience with human measles vector technology and an MV-SARS-CoV-1 candidate. (pasteur.fr)
  • NanoFlu is an influenza vaccine candidate which is a recombinant hemagglutinin protein nanoparticle influenza vaccine produced in an Sf9 insect cell-baculovirus system. (precisionvaccinations.com)
  • This review focuses on entry inhibitors that target the six-helical bundle core against highly pathogenic enveloped viruses with class I fusion proteins, including retroviruses, coronaviruses, influenza A viruses, paramyxoviruses, and filoviruses. (bvsalud.org)
  • 400 million poultry have been culled since 2003 as a result of efforts to control highly pathogenic H5N1 avian influenza ( http://www.fao.org/avianflu/en/index.html ), and there are increasing biological and ecological consequences. (nationalacademies.org)
  • Bender C, Hall H, Huang J, Klimov A, Subbarao K. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. (unt.edu)
  • And the reason for that is that the influenza A viruses change very quickly. (lindau-nobel.org)
  • Influenza has a genome with eight different segments, and if a cell gets infected, say with an influenza virus from humans and an influenza virus from a bird, and they're basically diseases of aquatic birds, they're maintained in nature in aquatic birds, then you can get a totally new influenza virus out. (lindau-nobel.org)
  • This recombinant human monoclonal antibody (VF0035) is specific for SARS-CoV S protein recognition. (creative-biolabs.com)
  • In 2020, CEPI was identified by several media outlets as a "key player in the race to develop a vaccine" for coronavirus disease 2019. (wikipedia.org)
  • OSLO, NORWAY, March 10, 2020 - CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of its COVID-19 vaccine portfolio. (hexdigital.com)
  • Novavax has produced and is currently assessing multiple nanoparticle vaccine candidates to identify the best candidate(s) for human testing, which is expected to begin by the end of spring 2020. (hexdigital.com)
  • OSLO, NORWAY I January 23, 2020 I CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the initiation of three programmes to develop vaccines against the novel coronavirus, nCoV-2019. (pipelinereview.com)
  • OSLO, NORWAY, March 19, 2020 - CEPI, the Coalition for Epidemic Preparedness Innovations, today added an eighth Covid-19 vaccine candidate to its portfolio. (pasteur.fr)
  • CEPI previously invested up to $10 million towards the cost of Phase 1/2 trials of in SK bioscience's vaccine candidate in December 2020, followed by an additional $26.7 million to begin adaptation against variants and support scale-up of manufacturing in March 2021. (cepi.net)
  • Novavax is creating COVID-19 vaccine candidates using its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. (hexdigital.com)
  • CEPI will be investing a further $4.4 million in partnering agreements with Novavax, Inc. and The University of Oxford to rapidly develop vaccine candidates against COVID-19. (hexdigital.com)
  • CEPI has so far invested in the development of 6 vaccine candidates against COVID-19. (hexdigital.com)
  • Fig. 1: Pipeline with vaccine candidates against COVID-19 grouped by technology platform. (internet1.de)
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases (EID). (wikipedia.org)
  • In 2022, CEPI adopted a vision for the world to be able to respond to a pandemic threat with a new vaccine within 100 days. (wikipedia.org)
  • The concept for CEPI was outlined in a July 2015 paper in The New England Journal of Medicine, titled "Establishing a Global Vaccine-Development Fund", co-authored by British medical researcher Jeremy Farrar (a director of Wellcome Trust), American physician Stanley A. Plotkin (co-discoverer of the Rubella vaccine), and American expert in infectious diseases Adel Mahmoud (developer of the HPV vaccine and rotavirus vaccine). (wikipedia.org)
  • Earlier this year, CEPI announced initial funding to Curevac Inc. , Inovio Pharmaceuticals Inc. , Moderna, Inc. , and University of Queensland to develop COVID-19 vaccine candidates using innovative platform technologies. (hexdigital.com)
  • The investments announced today are a result of a recent global call for proposals that CEPI issued in early February, which invited funding applications for proven vaccine technology that could be used to rapidly develop a vaccine against the new coronavirus, and most importantly at scale and with the necessary equitable access provisions. (hexdigital.com)
  • CEPI is working at speed to develop a vaccine, which will be crucial in the world's efforts to tackle this virus. (hexdigital.com)
  • On March 6, CEPI issued an urgent call for $2 billion of new funding to enable the organisation to expand the number of COVID-19 vaccine candidates in development and to fund the clinical trials for these candidate vaccines. (hexdigital.com)
  • CEPI still urgently needs additional financial contributions to ensure that the vaccine programmes we have initiated can continue to progress at their current pace. (hexdigital.com)
  • CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. (hexdigital.com)
  • CEPI has moved with great urgency and in coordination with WHO, who is leading the development of a coordinated international response, to promote the development of new vaccines against the emerging threat of nCoV-2019. (pipelinereview.com)
  • CEPI will invest an initial US$4.9 million in a partnering agreement with the Institut Pasteur-led consortium that will include Themis and the University of Pittsburgh to develop a vaccine candidate against Covid-19. (pasteur.fr)
  • In a first step, CEPI funding will support the preclinical testing, initial manufacture of vaccine materials, and preparatory work for phase 1 studies. (pasteur.fr)
  • CEPI was set up to accelerate the development of vaccines against emerging infectious threats like Covid-19. (pasteur.fr)
  • CEPI to provide up to US$173.4 million of additional funding to SK bioscience for its COVID-19 vaccine programme. (cepi.net)
  • CEPI, the Coalition for Epidemic Preparedness Innovations, and SK bioscience today announced an expanded partnership to develop a vaccine candidate against SARS-CoV-2, including variants of concern. (cepi.net)
  • To date, CEPI has invested in two vaccine candidates to tackle variants of concern, which can be made globally accessible through COVAX. (cepi.net)
  • The wholehearted support of CEPI and Gates Foundation reflects the technological level and potential value of our vaccine candidate. (cepi.net)
  • SK bioscience and CEPI are committed to enabling global equitable access to COVID-19 vaccines and have agreed that hundreds of millions of doses of this vaccine candidate will be made available to the COVAX Facility for procurement and equitable allocation worldwide, if proven to be safe and effective. (cepi.net)
  • The renewed partnership expands the scope of a previously launched collaboration ( announced in March 2021 ) in which CEPI committed up to US$33 million for VBI to develop an eVLP vaccine candidate targeting the Beta (B.1.351) COVID-19 variant. (vbivaccines.com)
  • We are grateful to CEPI for their continued support and our ongoing partnership as we optimize our technology to create vaccines that are capable of eliciting safe, durable, and broadly reactive immune responses. (vbivaccines.com)
  • The vaccine program has been developed through collaborations with CEPI, the National Research Council of Canada (NRC), and the Government of Canada, through their Strategic Innovation Fund. (vbivaccines.com)
  • Chikungunya virus (CHIKV) has become a global health problem. (blogspot.com)
  • We are evaluating a range of recombinant vaccine candidates, based on protein subunits as well as viral and mRNA vectors. (pirbright.ac.uk)
  • Inovio is advancing its MERS vaccine candidate into Phase 2, in the Middle East where most MERS viral outbreaks have occurred, with the support of its collaborators: The Wistar Institute, Laval University, the NIH's Rocky Mountain Laboratories, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), VGXI/GeneOne Life Science and the International Vaccine Institute. (pipelinereview.com)
  • Clinical manifestations are not specific and are difficult to differentiate from those of similar viral diseases (e.g., dengue and Zika virus disease). (blogspot.com)
  • We extended our structural and functional studies into the segmented negative strand RNA viruses that also use a single large protein to catalyze all the steps in viral gene expression. (whelan-lab.org)
  • We have employed those viruses in genome wide loss of function screens to probe the cellular factors for viral entry. (whelan-lab.org)
  • Clinically relevant involvement of the central nervous system (CNS) by viruses is an uncommon event, considering the overwhelming number of individuals affected by the different human viral infections. (medscape.com)
  • Our intention with this work is to leverage our work on the MERS coronavirus and rapid response platforms to speed up vaccine development. (pipelinereview.com)
  • The MERS DNA vaccine candidate is being developed using Inovio's DNA Medicines platform to deliver optimised synthetic antigenic genes into cells, where they are translated into protein antigens that activate an individual's immune system to generate robust targeted T cell and antibody responses. (pipelinereview.com)
  • It also has an open funding call to advance development of broadly protective coronavirus vaccines against SARS-CoV-2 and Betacoronaviruses , like SARS and MERS. (cepi.net)
  • As vaccine candidates we have advanced VSV-Zika, VSV-Oropouche, VSV-SARS, VSV-MERS and VSV-SARS-CoV-2. (whelan-lab.org)
  • As part of the safety lead-in portion of a phase 2 clinical trial in patients post HCT/CAR-T for hematological malignancies (HM), we tested the immunogenicity of the synthetic modified vaccinia Ankara-based COVID-19 vaccine COH04S1 co-expressing spike (S) and nucleocapsid (N) antigens. (bvsalud.org)
  • Recently, NiV B in African green monkeys resulted in a more severe and lethal disease than NiV M . No NiV vaccines or treatments are licensed for human use. (cdc.gov)
  • Identifying the key determinants of PRRSV proteins that mediate immune evasion or contribute to disease to provide rational targets for the production of attenuated vaccine strains. (pirbright.ac.uk)
  • Virulence of Newcastle disease virus (NDV) is mainly determined by the amino acid sequence surrounding the fusion (F) protein cleavage site, since host proteases that cleave the F protein of virulent strains are present in more tissues than those that cleave the F protein of non-virulent strains. (microbiologyresearch.org)
  • Pathogenesis of Newcastle disease in chickens experimentally infected with viruses of different virulence. (microbiologyresearch.org)
  • Deduced amino acid sequences at the fusion protein cleavage site of Newcastle disease viruses showing variation in antigenicity and pathogenicity. (microbiologyresearch.org)
  • Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. (microbiologyresearch.org)
  • Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease. (pipelinereview.com)
  • There are no guarantees of success, but we hope this work could provide a significant and important step forward in developing a vaccine for this disease. (pipelinereview.com)
  • Newcastle disease virus is a rubulavirus that infects poultry, penguins, and other birds and has been responsible for conjunctivitis in bird handlers and laboratory workers. (medscape.com)
  • All vaccines aim to expose the body to an antigen that does not cause disease but produces an immune response that can block or kill the virus when a person becomes infected. (internet1.de)
  • The recent Zika virus disease outbreak in South America also highlights the worldwide need for rapid reliable POC tests. (blogspot.com)
  • The EBOV is classified as a biosafety level 4 pathogen and is considered a category A agent of bioterrorism by Centers for Disease Control and Prevention, with no approved therapies and vaccines available for its treatment apart from supportive care. (biomedcentral.com)
  • VBI's eVLP technology is one such promising vaccine platform that could one day help protect the world against these and other new infectious disease threats. (vbivaccines.com)
  • Keeping animals healthy by employing sound principles of sanitation, management and feeding and by judicious use of appropriate and dependable vaccines are the practical and economical ways to avoid losses from the disease. (genemedi.com)
  • Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV) is an acute and highly contagious enteric disease of pigs, which leads to high morbidity and mortality in the suckling piglets, thereby bringing huge economic losses to the global pig industry. (cabi.org)
  • By dissecting the pathological and protective immune responses evoked by PRRSV, we will be able to design safer and more effective vaccines. (pirbright.ac.uk)
  • Novavax expects to use its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidate to enhance immune responses. (hexdigital.com)
  • We also aim to develop a safe and efficacious Nipah virus vaccine for pigs that will aid the prevention and control of Nipah outbreaks. (pirbright.ac.uk)
  • Our ambition is to have at least 3 vaccine candidates, which could be submitted to regulatory authorities for licensure for general use/use in outbreaks. (hexdigital.com)
  • Genetic variability of hepatitis E virus within and between three epidemics in India. (unt.edu)
  • Artpradit C, Robinson L, Gavrilov B, Rurak T, Ruchirawat M, Sasisekharan R. Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles. (cri.or.th)
  • As a proof-of-concept study, we used both minigenomes and recombinant viruses to test the inhibitory effects of previously reported antiviral compounds. (cdc.gov)
  • We previously described the synthesis of 1-O-octadecyl-2-O-benzyl-glycero-3-phospho-RVn (V2043), an orally bioavailable lipid prodrug of remdesivir nucleoside (RVn, GS-441524) with broad spectrum antiviral activity against viruses with pandemic potential. (cdc.gov)
  • We found that 3-F-4-MeO-Bn, 3-CN-Bn, and 4-CN-Bn sn-2 glycerol modifications improved antiviral activity compared to V2043 when tested in vitro against clinically important RNA viruses from 5 virus families. (cdc.gov)
  • Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. (cdc.gov)
  • In order to reduce the danger posed to humans by the new coronavirus SARS-CoV-2, a suitable vaccine is therefore feverishly sought worldwide. (internet1.de)
  • I suggest that psychopathic elements in the defense and intelligence agencies (and that's limited to high level members not the rank and file) and a handful of mad scientists and Dark Winter agents in the HHS conspired to hijack this well intentioned self spreading vaccine project and engineered a self spreading vaccine virus for humans and then released it. (substack.com)
  • Hendra virus (HeV) emerged as a zoonotic pathogen in the 1990s, causing low morbidity but high mortality in humans and horses. (cabi.org)
  • NeoVax is a personalized experimental vaccine designed to recognize cancer-specific proteins, called neoantigens, that are present on the individual's cancer cells but not on normal cells. (precisionvaccinations.com)
  • Higher eukaryotic structures, such as insect cells, may generate large quantities of recombinant proteins with complex post-translational modifications (PTMs), such that human proteins that cannot be expressed in bacteria. (helixbiogeninstitute.org)
  • Explore our comprehensive collection of recombinant Fc receptor proteins! (acrobiosystems.com)
  • Methods: Two approaches were used to determine the correlation between neutralizing antibody levels and outcomes following a severe (1,000 median lethal doses) intranasal/intratracheal (IN/IT) challenge with NiV (Bangladesh): (1) reduction in vaccine dose given 28 days before challenge and (2) challenge during the early phase of the antibody response to the vaccine. (bvsalud.org)
  • Results: Reduction in vaccine dose to very low levels led to primary vaccine failure rather than a sub-protective level of antibody. (bvsalud.org)
  • Discussion and conclusion: It was concluded that PHV02 vaccine elicited a rapid onset of protection and that any detectable level of neutralizing antibody was a functional immune correlate of survival. (bvsalud.org)
  • They change by mutation of the surface glycoproteins, the hemagglutinin, and the neuraminidase, which are selected by antibody-mediated pressures, and all lab vaccines are basically antibody-directed. (lindau-nobel.org)
  • nOPV2 Polio Vaccine is derived from the live, infectious virus that has been triple-locked using genetic engineering. (precisionvaccinations.com)
  • As part of CEPI's commitment to enabling equitable access, VBI agrees that vaccine candidates produced using their platform technology will be available in an outbreak situation to populations at risk including in low-income and middle-income countries, at a low but commercially sustainable price. (vbivaccines.com)
  • As we approach the third anniversary of the COVID-19 pandemic under the continued threat of new variants, we are determined to focus on the critical goal of developing future-proof coronavirus vaccines that will put the world ahead of this and other pandemic threats. (vbivaccines.com)
  • Funding for The University of Oxford project will support the manufacture of vaccine materials required for preclinical and phase 1 testing. (hexdigital.com)
  • NasoVAX is a recombinant intranasal vaccine that is RD-Ad5-based, being developed for both seasonal and pandemic use. (precisionvaccinations.com)
  • We are supporting the UK response to the COVID-19 pandemic by evaluating a range of vaccine candidates for immunogenicity in pigs to inform further clinical development. (pirbright.ac.uk)
  • The global pandemic has led to a strong emphasis on research into a suitable vaccine against COVID-19. (internet1.de)
  • Our versatile, plug-and-play manufacturing technology affords us the advantage of accelerating the discovery and development of a vaccine candidate against the highly infectious and potentially pandemic coronavirus. (pasteur.fr)
  • To achieve the goal against the pandemic, we will continue our highest efforts for the successful development and enlarged access to the COVID-19 vaccine that can also be preventive to variants utilizing our expanded manufacturing capabilities. (cepi.net)
  • The candidate vaccines will be developed using VBI's proprietary enveloped virus-like particle (eVLP) technology platform and aim to provide broad and durable protection against multiple variants of the COVID-19-causing coronavirus, as well as against other coronaviruses - both known and as-yet unknown - that harbour pandemic potential. (vbivaccines.com)
  • Broad spectrum oral antivirals are urgently needed for the early treatment of many RNA viruses of clinical concern. (cdc.gov)
  • The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible. (pipelinereview.com)
  • In the meantime, some vaccine candidates have already made it into clinical trials. (internet1.de)
  • Below you will find an overview of the vaccine candidates that have already been approved for clinical trials. (internet1.de)
  • We have demonstrated an excellent immunogenicity, safety and manufacturability profile of the technology in late stage clinical development already and are confident to apply this experience to our Covid-19 vaccine development. (pasteur.fr)
  • CEPI's funding will support Phase 3 clinical trials of SK bioscience's recombinant protein vaccine candidate (GBP510). (cepi.net)
  • Eastern, western, and Venezuelan equine encephalitis and West Nile viruses: clinical and public health considerations. (cabi.org)
  • Identification of ephrin-B2 and ephrin-B3 as cellular receptors for these viruses has enabled the development of immunotherapeutic reagents which prevent virus attachment and subsequent fusion. (ox.ac.uk)
  • NanoVax is an adjuvant platform used in the development of a vaccine candidate that will provide protection against the two viruses that can cause genital herpes. (precisionvaccinations.com)
  • Our major research focus is the development of improved vaccines for porcine reproductive and respiratory syndrome (PRRS). (pirbright.ac.uk)
  • In addition, we are applying our expertise in porcine immunology and vaccinology to contribute to the development of vaccines to combat new and emerging zoonotic viruses, such as the Nipah virus and SARS-CoV-2. (pirbright.ac.uk)
  • We are working with colleagues and collaborators on ambitious complimentary approaches aimed at the development of improved PRRS vaccines. (pirbright.ac.uk)
  • And to support the development of COVID-19 vaccine candidates by utilising the pig as a preclinical model to study vaccine immunogenicity. (pirbright.ac.uk)
  • Development of a Nipah virus vaccine to eliminate porcine reservoirs and safeguard human health. (pirbright.ac.uk)
  • These results support the continued development of V2043 and sn-2 glycerol modified RVn lipid prodrugs for the treatment of a broad range of RNA viruses for which there are limited therapies. (cdc.gov)
  • Vaccine development is complex and difficult and will require concerted global effort. (hexdigital.com)
  • Investing in vaccine development now is an investment in the future health of all our societies. (hexdigital.com)
  • An urgent, global, concerted effort is now needed to raise the money required to advance the development of COVID-19 vaccines. (hexdigital.com)
  • To date, the Governments of Germany, Norway, and the UK have committed $186 million towards our COVID-19 vaccine development efforts. (hexdigital.com)
  • The nCoV-2019 vaccine development efforts will build on existing partnerships with Inovio (Nasdaq: INO) and The University of Queensland (located in Brisbane, Australia). (pipelinereview.com)
  • All of these are pioneering technologies designed to speed up the development of vaccines against emerging threats such as nCoV-2019. (pipelinereview.com)
  • In addition, the Vaccine Centre at the London School of Hygiene & Tropical Medicine provides a tracker on its website that allows COVID-19 vaccine candidates to be tracked as they progress through the development phases. (internet1.de)
  • One of the ways we're doing this is by bridging the gap between public and private sectors to pool resources and expertise to jump start the vaccine development process. (pasteur.fr)
  • We are calling on the international community to contribute to the fight against Covid-19 by investing in CEPI's vaccine development programme, and help us deliver a long-term equitable solution to this unprecedented global challenge. (pasteur.fr)
  • The candidate vaccine is under development at Helix Biogen Institute Laboratory, which is undergoing animal trial. (helixbiogeninstitute.org)
  • Biologics drug discovery: Design and screen for lead compound using as a therapeutic drug or vaccine development using bacterial, insect-baculovirus expression system and mammalian expression system (HEK- 293 and CHO cell). (cri.or.th)
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the 'Coronavirus X' potential of VBI's technology. (vbivaccines.com)
  • Due to these dengue-specific complexities, vaccine development focuses on the generation of a tetravalent vaccine aimed at providing long-term protection against all virus serotypes. (medicofem.com)
  • In spite of these challenges, vaccine development has made remarkable progress in recent years, and the current dengue vaccine pipeline is advanced, diverse and overall promising. (medicofem.com)
  • Continued development of readily available vaccines for the. (cabi.org)
  • Virology work: Propagate virus under BSL-2 condition and perform related testing using virus as a test system for biologics efficacy or production inoculum. (cri.or.th)
  • The National Institute of Allergy and Infectious Diseases (NIAID) supported Regional Biocontainment Laboratories (RBL) housed at the Center for Vaccine Research is a state-of-the-art facility for research on Biosafety Level -3 (BSL-3) biodefense and emerging infectious diseases. (pasteur.fr)
  • HPIV-3 is second only to respiratory syncytial virus (RSV) as a cause of pneumonia and bronchiolitis in infants and young children. (medscape.com)
  • Chimpanzees, macaques, squirrels, owls, and rhesus monkeys have been asymptomatically infected with HPIV-3 or HPIV-4, and only marmosets have developed symptomatic upper respiratory tract infections (URTIs) with HPIV-3 and Sendai virus. (medscape.com)
  • After host cell entry via human angiotensin-converting enzyme II (hACE2), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can infect pulmonary epithelial cells, especially the AT2 (alveolar type II) cells that are crucial for maintaining normal lung function. (bvsalud.org)
  • Blydt-Hansen T, Subbarao K, Quennec P, McDonald J. Recovery of respiratory syncytial virus from stethoscopes by conventional culture and polymerase chain reaction. (unt.edu)
  • Respiratory viruses infect the human upper respiratory tract, mostly causing mild diseases. (mdpi.com)
  • Respiratory viruses can also exacerbate asthma and lead to various types of respiratory distress syndromes. (mdpi.com)
  • NiV is categorized as a Biosafety Level 4 (BSL-4) pathogen because of the substantial illness and death it causes and the lack of approved vaccines and therapeutic drugs for human use. (cdc.gov)
  • Research on therapeutic drug targets and vaccines for these viruses is limited because biosafety level 4 containment is required for handling them. (cdc.gov)
  • Although several promising therapeutic agents and vaccines against EBOV are undergoing the Phase I human trial, the current epidemic might be outpacing the speed at which drugs and vaccines can be produced. (biomedcentral.com)
  • adoptive transfer of genetically engineered t-cells to express antigen-specific t-cell receptor (tcr) is a feasible and effective therapeutic approach for numerous types of cancers, including epstein-barr virus (ebv)-associated malignancies. (liverpool.ac.uk)
  • Comparative pathogenesis of peste des petits ruminants virus strains of difference virulence. (vetbionet.eu)
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide. (vbivaccines.com)
  • The synthetic antigen can then be purified and rapidly manufactured into a vaccine. (pipelinereview.com)
  • Research progress of porcine epidemic diarrhea vaccine for pigs. (cabi.org)
  • The viruses attach to the host cells through hemagglutinin, which specifically combines with neuraminic acid receptors in the host cells. (medscape.com)
  • In 2019 the NIH funded a study on contagious vaccine transmission. (substack.com)
  • NEO-PV-01 Cancer vaccine candidate is a personal neoantigen vaccine which is custom designed and manufactured for each individual patient. (precisionvaccinations.com)
  • Funding will support Phase 3 trials of SK bioscience's recombinant protein vaccine candidate (GBP510) and adaptation for use against multiple variants of concern. (cepi.net)
  • CEPI's creation was also supported and co-funded by the pharmaceutical industry including GlaxoSmithKline (GSK), with CEO Sir Andrew Witty explaining at the WEF, "It is super-disruptive when the red phone rings in our vaccine division because of a health emergency. (wikipedia.org)
  • This brings CEPI's total investment in COVID-19 vaccine R&D to $23.7 million. (hexdigital.com)
  • We call on other sovereign states, private sector partners, and philanthropies around the world to invest in CEPI's crucial push to develop a vaccine against the COVID-19 virus. (hexdigital.com)